G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Bailey John E. (Jack) Jr. | President and CEO | May 13 '24 | Sale | 4.79 | 37,258 | 178,421 | 452,336 | May 15 04:06 PM | MURDOCK TERRY L | Chief Operating Officer | May 13 '24 | Sale | 4.79 | 8,151 | 39,034 | 95,487 | May 15 04:10 PM | Umstead John W. V | Chief Financial Officer | May 13 '24 | Sale | 4.79 | 8,151 | 39,034 | 153,245 | May 15 04:11 PM | Malik Rajesh | Chief Medical Officer | May 13 '24 | Sale | 4.79 | 8,151 | 39,034 | 161,787 | May 15 04:08 PM | Avagliano Mark | Chief Business Officer | May 13 '24 | Sale | 4.79 | 8,151 | 39,034 | 209,683 | May 15 04:07 PM | Umstead John W. V | Chief Financial Officer | Mar 18 '24 | Sale | 3.02 | 6,547 | 19,752 | 123,896 | Mar 20 04:32 PM | Malik Rajesh | Chief Medical Officer | Feb 12 '24 | Option Exercise | 0.30 | 28,600 | 8,580 | 198,538 | Feb 13 06:14 PM | Malik Rajesh | Chief Medical Officer | Feb 12 '24 | Sale | 4.62 | 28,600 | 132,143 | 169,938 | Feb 13 06:14 PM | MURDOCK TERRY L | Chief Operating Officer | Jan 04 '24 | Sale | 2.94 | 721 | 2,121 | 103,638 | Jan 08 06:00 AM | Avagliano Mark | Chief Business Officer | Jan 04 '24 | Sale | 2.94 | 721 | 2,121 | 117,834 | Jan 08 06:02 AM | Malik Rajesh | Chief Medical Officer | Jan 04 '24 | Sale | 2.94 | 721 | 2,121 | 169,938 | Jan 08 06:03 AM | Umstead John W. V | Chief Financial Officer | Jan 04 '24 | Sale | 2.94 | 111 | 327 | 130,443 | Jan 08 06:04 AM | Bailey John E. (Jack) Jr. | President and CEO | Jan 03 '24 | Sale | 3.12 | 11,686 | 36,447 | 489,594 | Jan 08 06:02 AM | Avagliano Mark | Chief Business Officer | Jan 03 '24 | Sale | 3.12 | 3,360 | 10,480 | 118,555 | Jan 08 06:02 AM | MURDOCK TERRY L | Chief Operating Officer | Jan 03 '24 | Sale | 3.12 | 3,019 | 9,416 | 104,359 | Jan 08 06:00 AM | Malik Rajesh | Chief Medical Officer | Jan 03 '24 | Sale | 3.12 | 3,019 | 9,416 | 170,659 | Jan 08 06:03 AM | Perry Andrew | Chief Commercial Officer | Jan 03 '24 | Sale | 3.12 | 2,413 | 7,526 | 87,102 | Jan 08 06:03 AM | Umstead John W. V | Chief Financial Officer | Jan 03 '24 | Sale | 3.12 | 632 | 1,971 | 130,554 | Jan 08 06:04 AM | Bailey John E. (Jack) Jr. | President and CEO | Jan 02 '24 | Sale | 3.27 | 32,983 | 108,006 | 400,580 | Jan 02 07:44 PM | Malik Rajesh | Chief Medical Officer | Dec 11 '23 | Option Exercise | 0.36 | 33,839 | 12,081 | 157,817 | Dec 13 04:45 PM | Malik Rajesh | Chief Medical Officer | Dec 11 '23 | Sale | 3.41 | 33,839 | 115,522 | 136,378 | Dec 13 04:45 PM | Velleca Mark A. | Director | Aug 08 '23 | Option Exercise | 0.39 | 60,000 | 23,156 | 173,286 | Aug 10 04:11 PM | Velleca Mark A. | Director | Aug 08 '23 | Sale | 2.00 | 60,000 | 119,974 | 116,000 | Aug 10 04:11 PM | Bailey John E. (Jack) Jr. | President and CEO | Jul 05 '23 | Sale | 2.45 | 2,719 | 6,672 | 433,563 | Jul 07 04:07 PM | MURDOCK TERRY L | Chief Operating Officer | Jul 05 '23 | Sale | 2.45 | 1,361 | 3,339 | 70,078 | Jul 07 04:08 PM | Malik Rajesh | Chief Medical Officer | Jul 05 '23 | Sale | 2.45 | 1,361 | 3,339 | 136,378 | Jul 07 04:08 PM | Perry Andrew | Chief Commercial Officer | Jul 05 '23 | Sale | 2.45 | 355 | 871 | 55,945 | Jul 07 04:08 PM |
|